Macquarie Group’s Pyxis Oncology PYXS Stock Holding History

Macquarie Group’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,113	Closed	-$5	–	2074
2024 Q1	$5	Buy	+1,113	New	+$4.68K	﹤0.01%	1795

Other funds holding PYXS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group's PYXS Position: Q2 2024 in Review

Macquarie Group sold out of Pyxis Oncology (PYXS) in Q2 2024, closing a stake of 1,113 shares — an estimated $5 sold.

Macquarie Group first reported a position in PYXS in Q1 2024 and held it in 1 quarter. The position peaked at $5 in Q1 2024. 80 funds tracked by Wall St. Rank hold PYXS as of Q2 2024.

Macquarie Group reported no remaining Pyxis Oncology position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 1,113 Pyxis Oncology shares in Q2 2024, an estimated $5.
Macquarie Group first reported a position in Pyxis Oncology in Q1 2024 and held it in 1 quarter.
Macquarie Group's Pyxis Oncology position peaked at $5 in Q1 2024.
80 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.